China Sky One gets R&D grant from govt
China Sky One Medical, a producer and distributor for external-Chinese medicine in China, has received a grant from the Heilongjiang government of $500,000 to perform monoclonal antibody R&D. China Sky One says it has been informed that it is the first company in the Heilongjiang province to receive such a government grant.
The company will work jointly with the China Nankai University to develop a monoclonal antibody that can be targeted to attach to a specific substance on cancer cells. The laboratory-produced monoclonal antibodies will be carefully engineered to target specific defects in cancer cells. The development of this monoclonal antibody drug may eventually lead to patents and the development of anti-tumor drugs.
MAb R&D is extensively supported by the Science Ministry of the People's Republic of China and its government currently encourages the cooperation between companies, universities, government agencies and institutions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze